These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 20336784

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
    Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD.
    Clin Cancer Res; 2013 Nov 01; 19(21):5960-71. PubMed ID: 24004674
    [Abstract] [Full Text] [Related]

  • 5. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Nakayama K, Rahman MT, Rahman M, Nakamura K, Ishikawa M, Katagiri H, Sato E, Ishibashi T, Iida K, Ishikawa N, Kyo S.
    Int J Oncol; 2016 Feb 01; 48(2):506-16. PubMed ID: 26647729
    [Abstract] [Full Text] [Related]

  • 6. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
    Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, Henderson B, Morrison LE, Birrer MJ, Gynecologic Oncology Group.
    Cancer Res; 2003 Mar 15; 63(6):1235-41. PubMed ID: 12649182
    [Abstract] [Full Text] [Related]

  • 7. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
    Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3319-28. PubMed ID: 16740753
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
    Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC.
    Clin Cancer Res; 2004 Oct 01; 10(19):6559-66. PubMed ID: 15475444
    [Abstract] [Full Text] [Related]

  • 11. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K.
    Clin Cancer Res; 2008 May 15; 14(10):3149-55. PubMed ID: 18483383
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    J Pathol Clin Res; 2020 Oct 15; 6(4):252-262. PubMed ID: 32391646
    [Abstract] [Full Text] [Related]

  • 14. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM.
    Clin Cancer Res; 2004 Aug 01; 10(15):5168-77. PubMed ID: 15297421
    [Abstract] [Full Text] [Related]

  • 15. CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma.
    Kawahara N, Yamada Y, Kobayashi H.
    Int J Mol Sci; 2021 May 30; 22(11):. PubMed ID: 34070839
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun 30; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 17. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
    Nakamura K, Abarzua F, Kodama J, Hongo A, Nasu Y, Kumon H, Hiramatsu Y.
    Int J Oncol; 2009 Feb 30; 34(2):345-53. PubMed ID: 19148468
    [Abstract] [Full Text] [Related]

  • 18. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 19. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
    Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA.
    Cancer; 2007 Sep 15; 110(6):1264-71. PubMed ID: 17647260
    [Abstract] [Full Text] [Related]

  • 20. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR.
    BMC Cancer; 2019 May 06; 19(1):422. PubMed ID: 31060523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.